Skip to content

Recent Additions in the Treatment of Depressive Disorders

New pharmacologic agents have become available for treating depressive disorders and their placement in therapy has yet to be fully elicited. This information is intended to help the pharmacist in determining where and how these new agents can be most effective.

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Summarize the safety and efficacy of the recently approved agents for major depressive disorder, treatment refractory depression, and post-partum depression.
  • Identify the appropriate patients who will benefit from these new therapies,
  • Recognize the expected impact of these newly approved antidepressants in the standard course of treatment for major depressive disorder, treatment refractory depression, and post-partum depression


Michael Angelini, BA, BS, MA, PharmD, BCPP, RPh 
Michael Angelini, BA, BS, MA, PharmD, BCPP, RPh is a Professor of Pharmacy Practice at MCPHS University in Boston, Massachusetts and a Psychiatric Clinical Pharmacist at Saint Luke’s Hospital in New Bedford, MA. He is also a Psychopharmacology Consultant for Commonwealth Pharmacy Services at the University of Massachusetts Medical School. Additionally, he has been a clinical consultant to primary care, community health centers and group homes throughout New England. He has served on faculty positions in the Addiction Fellowship Program at Boston University School of Medicine, the Massachusetts School of Professional Psychology, and Harvard Medical School. Dr. Angelini earned his Master’s degree in Clinical Psychology at Boston University and his Doctor of Pharmacy degree at MCPHS University. Board-certified in Psychiatric Pharmacy, Dr. Angelini has published chapters in therapeutics textbooks, study guides and articles in peer-reviewed journals. Dr. Angelini is a member of the American Association of Colleges of Pharmacy and the Massachusetts Pharmacists Association.

Registration Fee: Free for MCPHS alumni, faculty and staff. For all others the fee is $12.00


Release Date: December 4, 2020
Expiration Date: December 7, 2022
Contact Hours: 1.0
Universal Activity Number: 0026-0000-20-207-H01-P | Knowledge-based
ACPE Topic Designator: Disease State Management/Drug Therapy


ACPE logo

Requirements for Credit

In order to receive credit, the participant must view the entire presentation and complete the pre and post-test, and evaluation. Upon completion participant credit will be reported to CPE Monitor. Transcripts may be printed from CPE Monitor.

Statement of Disclosure

It is the policy of MCPHS-CE to ensure balance, independence, objectivity and scientific rigor in all of its educational activities. All individuals engaged in the planning of a continuing education activity and who are in a position to control the educational content are required to disclose any financial relationships with ineligible companies occurring within the past 24 months. The intent of this policy is to identify and mitigate any potential conflict of interest that may directly or indirectly affect the activity. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

MCPHS will identify, review and mitigate all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Michael Angelini has no relevant financial relationships with ineligible companies to disclose.

Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies, related to the content of this presentation.

No funding from industry provided for this event. No exhibitors will be present.